Latest Conference Articles

A novel treatment combining EIK1001 with pembrolizumab shows promising response rates in advanced non-small cell lung cancer, enhancing patient outcomes.

Emerging research highlights the rising incidence of early-onset neuroendocrine tumors, revealing unique challenges and symptom burdens in younger patients.

Nivolumab plus ipilimumab shows significant progression-free survival benefits in metastatic colorectal cancer, establishing a new standard of care.

New research compares transarterial embolization and chemoembolization for treating neuroendocrine liver metastases, revealing unexpected safety differences.

New research reveals that sustained MRD negativity after ASCT allows safe discontinuation of lenalidomide maintenance in multiple myeloma patients.

A phase 1 trial reveals camu camu's safety and potential benefits in melanoma and NSCLC patients undergoing immune checkpoint therapy.

Phase 2 trial CALYPSO reveals no improvement in outcomes for advanced renal cell carcinoma with savolitinib addition, prompting reevaluation of treatment strategies.

Bradley Monk, MD, highlights transformative long-term outcomes from the innovaTV trial, showcasing innovative treatments for cervical cancer at ESMO 2025.

New findings reveal that adding sapanisertib to weekly paclitaxel significantly improves progression-free survival in advanced ovarian cancer patients.

Scott Tagawa, MD, highlights the PSMAddition trial's promising results, showcasing Lutetium-177 PSMA-617's significant benefits for advanced prostate cancer treatment.

Dr Bradley J. Monk explores the RUBY trial's findings, highlighting the survival benefits of adding dostarlimab to chemotherapy for endometrial cancer treatment.

Triplet therapy of ciforadenant, nivolumab, and ipilimumab shows safety but lacks efficacy in advanced clear cell kidney cancer.

A groundbreaking study reveals the effectiveness of dabrafenib and trametinib in treating advanced thyroid cancer, showcasing significant survival benefits.

Combination therapy of percutaneous hepatic perfusion with immune checkpoint inhibitors shows promising survival rates in metastatic uveal melanoma patients.

Recent studies reveal that triplet therapies significantly enhance progression-free survival in patients with endocrine-resistant breast cancer.

Camrelizumab and famitinib significantly enhance progression-free survival in recurrent cervical cancer compared to traditional chemotherapy, offering a promising new treatment option.

Bemarituzumab combined with mFOLFOX6 shows promising overall survival benefits in advanced FGFR2b-overexpressing gastric cancer, despite safety concerns.

New findings from the EMBARK trial reveal enzalutamide significantly reduces mortality risk in high-risk prostate cancer patients, enhancing treatment options.

Alectinib shows remarkable 4-year survival rates in early-stage ALK-positive lung cancer, outperforming chemotherapy in disease-free survival and CNS recurrence.

Atezolizumab significantly enhances survival in ctDNA-positive muscle-invasive bladder cancer patients, addressing critical treatment gaps post-surgery.

Pembrolizumab significantly improves survival rates in early-stage non-small cell lung cancer, establishing a new standard of care in perioperative therapy.

Atezolizumab significantly enhances disease-free and overall survival in ctDNA-positive muscle-invasive bladder cancer patients, reshaping treatment strategies.

Zanzalintinib combined with atezolizumab significantly improves overall survival in metastatic colorectal cancer compared to regorafenib, offering new hope for patients.

Telisotuzumab adizutecan shows promising antitumor activity in advanced pancreatic cancer, with manageable safety and significant clinical benefits in a phase 1 study.

Combination therapy with sacituzumab govitecan and pembrolizumab enhances quality of life and delays physical decline in metastatic triple-negative breast cancer patients.

Disitamab vedotin plus toripalimab significantly enhances survival rates in HER2-expressing advanced urothelial carcinoma, outperforming standard chemotherapy.

New findings reveal that perioperative enfortumab vedotin and pembrolizumab significantly enhance survival rates in muscle-invasive bladder cancer patients.

Combination therapy with datopotamab deruxtecan and rilvegostomig shows significant antitumor activity in advanced urothelial cancer patients.

A phase 2 study reveals lenvatinib and everolimus significantly improve progression-free survival in metastatic clear cell RCC compared to cabozantinib.